CEO
Jason Lettmann has served as ALX Oncology’s chief executive officer since September 2023 and as a board member since April 2020. He previously served as a member of ALX Oncology’s board of directors from March 2015 to May 2017. Previously, Jason was a general partner of Lightstone Ventures from March 2012 to July 2023 and a partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He previously served as chief executive officer of Promedior, a biotechnology company acquired by Roche, from January 2019 to February 2020 and as vice president at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Jason has been a member of the board of directors of several public and privately held companies, including Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB. He holds a Bachelor of Arts degree in psychology from the University of Iowa and an MBA from the University of Michigan’s Ross School of Business.